OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Chronic myelogenous leukemia is a rare type of cancer that the increased and uncontrolled growth of myeloid cells in the bone marrow and the accumulation of these cells in the blood. Most of them people don’t know that they are infected with this kind of rare cancer and report shows that due to the smoking habits and exposure to high radiation for the time period.
Treatment:
Treatment of refractory chronic lymphocytic leukemia may include the following: Repeat treatment with monoclonal antibody therapy and combination chemotherapy. A clinical trial of chemotherapy with stem cell transplant.
Major research on disease:
CLL patients are encouraged to explore clinical trials. Clinical trials test new drugs and treatments, many of which are being supported by LLS research programs, before they are approved by the FDA as standard treatment. Present ongoing present trend of clinical researched are follows Kinase Inhibitor Therapy, Monoclonal Antibody, Immunomodulatory Drug and Improvements in Stem Cell Transplantation.
Statistics
American Cancer Society's estimates for chronic myeloid leukemia (CML) in the United States for 2015 are: About 6,660 new cases will be diagnosed with CML (3,530 in men and 3,130 in women). About 1,140 people will die of CML (590 men and 550 women). A little over 10% of all new cases of leukemia are chronic myeloid leukemia. About 1 person in 555 will get CML in their lifetime in the United States. The average age at diagnosis of CML is around 64 years. Almost half of cases are diagnosed in people 65 and older. This type of leukemia mainly affects adults, and is only rarely seen in children.